Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maymetsi, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control as part of a comprehensive treatment plan. - Inadequate control on metformin alone: provides additional glucose‑lowering effect when combined with lifestyle measures. - Adults with high cardiovascular risk: may offer modest benefit when added to standard therapy.

Maymetsi may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, usually transient. - Headache: mild cranial discomfort. - Upper respiratory tract infection: nasopharyngitis symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: acute inflammation of the pancreas. - Anaphylactic reaction: rare severe allergic response.

Before initiating Maymetsi, several safety considerations should be reviewed.

- Renal function assessment: evaluate creatinine clearance prior to therapy. - Risk of lactic acidosis: avoid in patients with severe renal impairment. - Monitor for hypoglycaemia: especially when used with insulin or sulfonylureas. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Maymetsi can interact with several medicines; understanding the level of risk helps guide safe use.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of renal impairment; discontinue metformin before imaging. - Insulin or sulfonylureas: may cause severe hypoglycaemia. - Strong CYP3A4 inducers (e.g., rifampin): may reduce sitagliptin exposure.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Corticosteroids: can raise blood glucose, requiring dose adjustment.